Cumberland Pharmaceuticals completes $100 million transaction and announces NDA filing and trial results
Cumberland Pharmaceuticals reported its Q3 2026 results, noting the July 1 closing of a $100 million strategic transaction with Apotex Health. The company said it will submit a New Drug Application to the FDA for ifetroban to treat Duchenne muscular dystrophy‑related cardiomyopathy and disclosed top‑line data from a Phase 2a systemic sclerosis trial. Net income for the quarter was $77.8 million and cash stood at $80.6 million.
Why it matters
The $100 million proceeds strengthen Cumberland’s balance sheet and fund its clinical pipeline, which may affect future cash flows and valuation. The planned NDA filing and positive trial data could drive future revenue if the products receive approval.
Key facts
- 1The strategic transaction with Apotex Health closed on July 1, 2026, providing $100 million in proceeds. prnewswire.com
- 2Cumberland plans to submit an NDA to the FDA for ifetroban as a treatment for DMD‑associated cardiomyopathy. prnewswire.com
- 3Phase 2 FIGHT DMD trial showed a 5.4‑percentage‑point improvement in left ventricular ejection fraction (p=0.002). prnewswire.com
- 4Top‑line results were announced from the Phase 2a ASSIST‑SSc trial of ifetroban in systemic sclerosis. prnewswire.com
- 5Net income for Q3 2026 was $77.8 million, including gains from the divestiture of transaction assets. prnewswire.com
- 6Cash and cash equivalents were $80.6 million as of September 30, 2026. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.